Shanghai Yizhong Pharmaceutical Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shanghai Yizhong Pharmaceutical Co., Ltd.

Why is Shanghai Yizhong Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 196.91% and Operating profit at 48.07% over the last 5 years

The company has declared Negative results for the last 5 consecutive quarters

OPERATING CASH FLOW(Y) Lowest at CNY -5.77 MM
DEBT-EQUITY RATIO (HY) Highest at 0 %
DEBTORS TURNOVER RATIO(HY) Lowest at 0 times

With ROE of 0.29%, it has a very expensive valuation with a 8.35 Price to Book Value

Over the past year, while the stock has generated a return of 12.49%, its profits have fallen by -95.4%
At the current price, the company has a high dividend yield of 0

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Shanghai Yizhong Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Shanghai Yizhong Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Shanghai Yizhong Pharmaceutical Co., Ltd.

43.73%

1.58

57.47%

China Shanghai Composite

16.01%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

196.91%

EBIT Growth (5y)

48.07%

EBIT to Interest (avg)

80.83

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.43

Sales to Capital Employed (avg)

0.18

Tax Ratio

39.09%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

32.26%

ROE (avg)

7.02%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

2847

Industry P/E

Price to Book Value

8.35

EV to EBIT

-972.78

EV to EBITDA

11520.41

EV to Capital Employed

13.06

EV to Sales

54.64

PEG Ratio

Dividend Yield

ROCE (Latest)

-1.34%

ROE (Latest)

0.29%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

27What is working for the Company

PRE-TAX PROFIT(Q)

At CNY 11.64 MM has Grown at 466.46%

NET PROFIT(Q)

At CNY 13.47 MM has Grown at 255.9%

RAW MATERIAL COST(Y)

Fallen by -94.68% (YoY

NET SALES(Q)

At CNY 73.95 MM has Grown at 19.83%

-8What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY -5.77 MM

DEBT-EQUITY RATIO (HY)

Highest at 0 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 0 times

INVENTORY TURNOVER RATIO(HY)

Lowest at 0 times

Here's what is working for Shanghai Yizhong Pharmaceutical Co., Ltd.

Pre-Tax Profit

At CNY 11.64 MM has Grown at 466.46%

over average net sales of the previous four periods of CNY 2.05 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 13.47 MM has Grown at 255.9%

over average net sales of the previous four periods of CNY 3.79 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Net Sales

At CNY 73.95 MM has Grown at 19.83%

over average net sales of the previous four periods of CNY 61.71 MM

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Raw Material Cost

Fallen by -94.68% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shanghai Yizhong Pharmaceutical Co., Ltd.

Operating Cash Flow

Lowest at CNY -5.77 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Debt-Equity Ratio

Highest at 0 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 0 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Inventory Turnover Ratio

Lowest at 0 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio